A 5mg vial reconstituted with 2mL of bacteriostatic water produces 2.5mg/mL
Phase 2 trial data (published in New England Journal of Medicine, 2023 ): 24.2% average weight loss at 48 weeks with 12 mg dose 22.8% with 8 mg dose Placebo group lost 2.1% Most recent Phase 3 trial data (TRIUMPH-4, December 2025): 28.7% average weight loss at 68 weeks with 12 mg dose 26.4% with 9 mg dose 58.6% of participants on 12 mg achieved at least 25% weight loss 39.4% achieved at least 30% weight loss For context: These are the highest weight loss numbers reported in any clinical trial for a pharmacological obesity treatment
Information on ongoing trials can be found via NIHR Be Part of Research (bepartofresearch.nihr.ac.uk), ClinicalTrials.gov , or the ISRCTN registry
Exosomes Exosomes are nano-sized extracellular vesicles derived from various cells
TripleHormone-Receptor Agonist Retatrutide for Obesity (Phase 2 Trial)
Globally, obesity rates are accelerating significantly, compelling the healthcare professionals to prescribe these drugs mainly for their certified efficacy in facilitating weight loss, particularly in diabetic patients
